Recalled Because the Factory Was Not on Your Licence: NHP Site Licence Scope and Foreign Building Listings

In September 2026, Health Canada recalled three Organika gummy products for a reason that had nothing to do with the product inside the bottle. The recall notice, RA-82618, states the cause in one line: the affected lots were imported from a foreign manufacturing site that was not listed on the company's site licence. There was no contamination, no potency failure and no label error. The product was recalled because of where it was made, and because that place was not written on a licence.

For natural health product (NHP) importers and virtual manufacturers, this is the compliance failure that hides in plain sight. Your supplier can be fully qualified, your batch records can be clean and your certificate of analysis can be flawless, and you can still face a recall if the building that made your product is not named on your site licence. This article explains what a site licence actually covers, why the Organika recall matters now, and exactly what licence holders should verify and fix, especially under the stricter expectations of GUI-0158 Version 4.0.

Executive summary

The essentials for busy licence holders:

• Health Canada recall RA-82618, published 15 September 2026, pulled three Organika NHP gummies because they were made at a foreign site not listed on the company's site licence. The recall was classified Type III.
• A site licence authorises specific activities at specific named buildings, in Canada and abroad. If a building is not on the licence, product handled there is not covered.
• GUI-0158 Version 4.0, enforceable since 4 March 2026, raises the bar for importers. A foreign manufacturer's GMP claim is no longer enough on its own.
• The obligation sits with the licence holder, not the contract manufacturer. When sourcing shifts to a new building, the licence must catch up before product ships.
• The fix is a site licence amendment plus a supplier qualification programme that keeps the building list and the real supply chain in step.

What a natural health product site licence actually covers

A site licence is the authorisation that lets a company manufacture, package, label or import NHPs in Canada. Under the Natural Health Products Regulations (SOR/2003-196), it is tied to specific buildings and specific activities. Every building where a licensable activity happens, including a foreign manufacturing site, must be identified on the licence.

The licensable activities are manufacturing, packaging, labelling and importing. A site licence lists each building where the licence holder carries out one or more of these activities, and it records the good manufacturing practices (GMP) evidence that supports each building and activity. A domestic company that imports a finished NHP made abroad is still conducting a licensable activity, importing, and the foreign building that manufactured the product forms part of the licensed supply chain. The licence is, in effect, a map of who does what and where. When the real supply chain and the map disagree, the licence is the version Health Canada enforces.

The responsibility is personal to the licence holder. If you hold the site licence, you are accountable for ensuring that every building that manufactures, packages or labels your product is properly reflected on it, with current GMP evidence. You cannot delegate that accountability to a broker, a distributor or the foreign manufacturer. This is the point most importers underestimate, and it is exactly the point the Organika recall turns on.

What went wrong in the Organika recall (RA-82618)

Health Canada recalled three Organika gummy products on 15 September 2026 because affected lots were imported from a foreign manufacturing site that was not listed on the site licence. The issue category is establishment and site licensing, not product quality, and the recall was classified Type III. In plain terms, the product itself was not alleged to be unsafe. The licence did not cover where it was made.

The three affected products, as published in the recall notice, were:

A Type III classification signals that use of the product is not likely to cause an adverse health consequence. That is cold comfort. A recall is still a public event, a market withdrawal, a cost, and a documented compliance failure that an inspector will read as a symptom of a weak quality system. If you want the full picture of what each class signals, see how Canada classifies a Type III recall. The lesson here is not about severity. It is that a licensing gap alone is enough to trigger a recall, with no product defect required.

Why GUI-0158 Version 4.0 raises the stakes in 2026

GUI-0158 Version 4.0, the good manufacturing practices guide for NHPs, has been enforceable since 4 March 2026. Its most consequential shift for importers is that a foreign manufacturer's GMP claim, on its own, is no longer sufficient. The Canadian licence holder is expected to hold and act on real evidence, not to rely on a foreign attestation.

Under the updated NHP GMP Guide Version 4.0, importers are expected to hold quality agreements with their foreign sites, to perform documented batch documentation review, and to make and record a positive release decision before product reaches the Canadian market. Each of those controls assumes you know precisely which building made the batch. If sourcing quietly moves to a sister plant, a new contract manufacturer or an additional line in another country, and your site licence and your quality file do not record it, every downstream control is built on a false premise.

This is why the site licence building list and the GMP evidence file have to be maintained as one living system, not two separate paperwork exercises. Our GUI-0158 Version 4.0 compliance checklist walks through the controls Health Canada now expects importers to demonstrate, and the Organika recall is a live example of what happens when the building list falls out of step with actual sourcing.

When must a foreign manufacturing site be on your licence?

A foreign building must be on your site licence whenever it manufactures, packages or labels the finished NHP you import. The test is not whether you have a good relationship with the supplier or a certificate on file. It is whether a licensable activity for your product physically happens at that building. If it does, the building belongs on the licence before you ship.

The grey area most companies stumble on is the difference between a raw material supplier and a finished product manufacturer, because that distinction decides what has to be listed. If you are not sure which side of the line a given input falls on, work through the raw material or finished NHP classification test first. The scenarios below show the common cases.

How to amend an NHP site licence to add a foreign building

To add a foreign building, the licence holder files a site licence amendment with Health Canada's Natural and Non-prescription Health Products Directorate, supported by GMP evidence for that building and activity. Until the amendment is reflected on the licence, product manufactured, packaged or labelled at the new building should not be released to the Canadian market.

A practical sequence looks like this:

1. Map your real supply chain. List every building that manufactures, packages or labels each product, and compare it against what your licence actually says.
2. Identify every gap. Flag any building that is active in your supply chain but missing from the licence, and stop releasing product from those buildings until the gap is closed.
3. Assemble GMP evidence for the building. This is the objective evidence that the site meets Canadian GMP expectations for the activity it performs, held by you as the licence holder.
4. File the site licence amendment. Submit the amendment to add the building and activity, with the supporting evidence, through the directorate's site licensing process.
5. Hold shipment from the new building until the amended licence is issued and the building appears on it.
6. Build a change trigger. Put a control in place so that any change of manufacturing building automatically triggers a licence review, as part of a supplier qualification programme that keeps the licence and the supply chain aligned.

Health Canada's service standards for site licence amendments vary with the type of change and the completeness of the evidence, so build in lead time and treat the change as planned work rather than a same-week fix. The costly mistake is commercial pressure to ship first and paper the licence later. That is precisely the sequence that ends in a recall notice.

NHP site licence scope compliance checklist

• Every building that manufactures, packages or labels each product is listed on your current site licence.
• The activities recorded on the licence match what each building actually does for you.
• You hold current GMP evidence for every listed foreign building and activity.
• A signed quality agreement is in place with each foreign manufacturer and packager.
• Documented batch documentation review is performed before each Canadian release.
• A change control procedure treats any change of manufacturing building as a licence-review trigger.
• No product is released from a building until that building appears on the amended licence.
• A periodic reconciliation compares the licence building list against the real supply chain at least annually.
• A mock recall has tested whether you can trace a lot back to the correct manufacturing building.

Common mistakes that lead to a site licence recall

• Treating a supplier certificate as a substitute for a site licence listing. A qualified supplier is not the same as a licensed building.
• Letting procurement change manufacturing buildings without telling quality or regulatory. Sourcing decisions become licensing events.
• Assuming a sister plant is covered because the parent company is already listed. Each building is assessed on its own.
• Shipping first and filing the amendment later. Product handled at an unlisted building is exposed from the first lot.
• Never reconciling the licence against the supply chain, so the gap only surfaces during an inspection or a recall.
• Assuming the contract manufacturer carries the risk. The obligation attaches to the licence holder, not the factory.

Frequently asked questions

Do I need to add a foreign manufacturer to my NHP site licence?

Yes, if that foreign building manufactures, packages or labels the finished NHP you import. Those are licensable activities, and the building where they happen must be identified on your site licence with supporting GMP evidence. A foreign supplier that provides only a raw material, and not the finished product, is generally not listed, but it still has to be qualified and controlled.

What happens if my NHP is made at a site not on my site licence?

The product can be recalled on that basis alone, even with no quality defect. That is exactly what happened with Health Canada recall RA-82618, where three Organika gummy products were recalled because the lots came from a foreign site not listed on the licence. The issue was classified as establishment and site licensing, not product safety.

How long does an NHP site licence amendment take?

It depends on the type of change and the completeness of your GMP evidence. Health Canada applies service standards to site licence applications and amendments, and a well-supported amendment moves faster than one that triggers questions. Plan the change in advance and do not ship from the new building until the amended licence is issued.

Who is responsible when a contract manufacturer is not listed?

The site licence holder. Accountability for keeping the building list accurate sits with the company that holds the licence, not with the contract manufacturer. You cannot transfer that responsibility to the factory, the broker or the distributor, which is why importers carry the exposure when a building is missing.

Does every foreign site in my supply chain need to be on the licence?

Every foreign building that performs a licensable activity for your finished product does. Manufacturing, packaging and labelling sites must be listed. Raw material suppliers generally are not listed, but they must be qualified through your supplier programme. The safest approach is to map the whole chain and decide each building on the activity it performs.

What does GUI-0158 Version 4.0 change for importers?

It confirms that a foreign GMP claim alone is not enough. Enforceable since 4 March 2026, the guide expects importers to hold quality agreements, perform documented batch documentation review and record a positive release decision. All of those controls depend on knowing, and correctly listing, the exact building that made each batch.

How MFLRC can help

MF License and Regulatory Consultants works with NHP importers and virtual manufacturers on exactly this gap. We review your site licence against your real supply chain, identify every building that is active but unlisted, and map the amendments you need to file. From there we build the supporting GMP evidence packages, draft the importer quality agreements, and design the supplier qualification and change-control procedures that keep the licence and the supply chain in step. We also run mock recalls to test whether you can trace a lot to the correct building before Health Canada does. If you want the wider picture first, start with our overview of NHP compliance in Canada, or see how to run a recall simulation. Our services span licensing support, gap assessments, SOP development, QAP services, audits and Compliance-as-a-Service retainers for licence holders.

Conclusion

The Organika recall is a warning that has nothing to do with product quality and everything to do with paperwork that fell behind the business. Most NHP importers discover the gap during a recall, not before one. The remedy is not complicated, but it is deliberate: map the supply chain, reconcile it against the licence, file the amendments, and put a change control in place so it never drifts again. With GUI-0158 Version 4.0 now enforced and the NHP Quality Guide consultation pointing toward tighter expectations still, the licence holders who reconcile now are the ones who will not read their own company name in a recall notice next year.

Sources and references

• Health Canada, Recall RA-82618: Organika Gummies, foreign site not listed on site licence (15 September 2026).
• Health Canada, Good manufacturing practices guide for natural health products (GUI-0158).
• Health Canada, GUI-0158 Version 4 notice (4 September 2025), enforceable 4 March 2026.
• Natural Health Products Regulations (SOR/2003-196), Justice Laws Website.
• Health Canada, Site licensing guidance document for natural health products.